Article
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.
Oncology research and treatment - 1 Jan 2015
Gautschi Oliver, Stadelmann Carola, Aebersold-Keller Franziska, König Katharina, Büttner Reinhard, Heukamp Lukas C, Betticher Daniel, Baumann Christa, Buser Katharina, Calderoni Antonello, Casty Adrian, DʼAddario Giannicola, Irlé Claudius, Mamot Christoph, Morant Rudolf, Trojan Andreas, Pellicioli Erica, Jehle-Schwertfeger Sonja, Aebi Stefan, Diebold Joachim
Abstract excerpt
BACKGROUND: The role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and unknown EGFR mutation status has recently been questioned. PATIENTS AND METHODS: We conducted a retrospective study of patients with unknown EGFR mutation status and long-term response (LTR) to gefitinib in the Swiss Iressa expanded...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.